Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes

Authors

Kevan C Herold, Yale University
Jing Hughes, Washington University School of Medicine in St. Louis
Janet B McGill, Washington University School of Medicine in St. Louis
et al

Journal

JCI Insight

Publication Date

12-19-2019

Volume

4

Issue

24

First Page

e126054

Document Type

Open Access Publication

DOI

10.1172/jci.insight.126054

Rights and Permissions

Herold KC, Bucktrout SL, Wang X, Bode BW, Gitelman SE, Gottlieb PA, Hughes J, Joh T, McGill JB, Pettus JH, Potluri S, Schatz D, Shannon M, Udata C, Wong G, Levisetti M, Ganguly BJ, Garzone PD; RN168 Working Group. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. JCI Insight. 2019 Dec 19;4(24):e126054. doi: 10.1172/jci.insight.126054. PMID: 31852846; PMCID: PMC6975260.

Recommended Citation

Herold, Kevan C; Hughes, Jing; McGill, Janet B; and et al, "Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes." JCI Insight. 4, 24. e126054 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/9712